Martin Glas
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
Feb 14, 2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Feb 14, 2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018; 20:975-985.
Jun 18, 2018Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Jun 18, 2018Neuro Oncol 2018; 20:975-985
Schäfer Niklas, Proescholdt Martin, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Grauer Oliver, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Grau Stefan, Hänel Mathias, Schnell Oliver, Krex Dietmar, Vajkoczy Peter, Tabatabai Ghazaleh, Mack Frederic, Schaub Christina, Tzaridis Theophilos, Nießen Michael, Kebir Sied, Leutgeb Barbara, Urbach Horst, Belka Claus, Stummer Walter, Glas Martin, Herrlinger Ulrich
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Nießen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann R, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J Cancer Res Clin Oncol 2018; 144:1581-1589.
May 28, 2018Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
May 28, 2018J Cancer Res Clin Oncol 2018; 144:1581-1589
Schaub Christina, Kebir Sied, Junold Nina, Hattingen Elke, Schäfer Niklas, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Goldbrunner Roland, Nießen Michael, Mack Frederic, Stuplich Moritz, Tzaridis Theophilos, Bähr Oliver, Kortmann Rolf-Dieter, Schlegel Uwe, Schmidt-Graf Friederike, Rohde Veit, Braun Christian, Hänel Mathias, Sabel Michael, Gerlach Rüdiger, Krex Dietmar, Belka Claus, Vatter Hartmut, Proescholdt Martin, Herrlinger Ulrich, Glas Martin
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611-9.
Mar 14, 2016Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Mar 14, 2016J Clin Oncol 2016; 34:1611-9
Herrlinger Ulrich, Kortmann Rolf-Dieter, Mehdorn Maximilian, Tüttenberg Jochen, Mayer-Steinacker Regine, Fietkau Rainer, Brehmer Stefanie, Mack Frederic, Stuplich Moritz, Kebir Sied, Kohnen Ralf, Dunkl Elmar, Leutgeb Barbara, Proescholdt Martin, Pietsch Torsten, Urbach Horst, Belka Claus, Stummer Walter, Gerlach Rüdiger, Vajkoczy Peter, Schäfer Niklas, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Maciaczyk Jaroslaw, Grau Stefan, Schnell Oliver, Hänel Mathias, Krex Dietmar, Glas Martin
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Scholz A, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh J, Ullrich E, Mittelbronn M, Plate K, Krex D, Herrlinger U, Glas M, Harter P, Cremer S, Yalcin B, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach J, Trojan J, Reiss Y. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med 2015; 8:39-57.
Dec 14, 2015Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Dec 14, 2015EMBO Mol Med 2015; 8:39-57
Scholz Alexander, Meinhardt Matthias, Weyerbrock Astrid, Timmer Marco, Goldbrunner Roland, Deckert Martina, Braun Christian, Schittenhelm Jens, Frueh Jochen T, Ullrich Evelyn, Mittelbronn Michel, Plate Karl H, Krex Dietmar, Herrlinger Ulrich, Glas Martin, Harter Patrick N, Cremer Sebastian, Yalcin Burak H, Gurnik Stefanie, Yamaji Maiko, Di Tacchio Mariangela, Sommer Kathleen, Baumgarten Peter, Bähr Oliver, Steinbach Joachim P, Trojan Jörg, Reiss Yvonne